Industry News (Joint Venture)

Agreement Signed To Gain White Blood Cell Access for Drug Development

Published in Medical Letter on the CDC and FDA, September 28th, 1998

Viragen, Inc., Plantation, Florida, and Viragen USA, Inc., announced that they have entered into an agreement with The American Red Cross (ARC) to obtain ARC's human leukocytes (white blood cells) for up to 15 years for the production of therapeutic drugs, including natural interferon.

Viragen uses white blood cells as the source material for the manufacture of Omniferon, a multi-subtype, highly purified natural alpha interferon drug currently in preclinical studies. The company expects to complete such studies by the end of 1998 and commence human studies in hepatitis C shortly thereafter. In addition, Viragen will also use white blood cells for the manufacture of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (1998-09-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry